[The treatment of different forms of B and delta hepatitis with interferon preparations].
A study was made of the therapeutic efficacy of human leukocytic interferon (HLI) and leikinferon in the treatment of HBV- and HDV-infection. 21 patients were placed under observation. Of these, 6 presented with lingering hepatitis B (HB), 8 with chronic HB, 1 was a HBsAg carrier, 4 had Grades I-IV, acute hepatic encephalopathy, and 2 acute hepatitis delta. 15 patients received leikinferon, 6 were given HLI for injections. Indications and schemes for the treatment with interferon preparations are provided as are the clinico-biochemical and serological criteria for estimating the efficacy of interferon therapy. In lingering and chronic forms of HB, leikinferon exerts a beneficial effect. It is not costly, thus enabling one to carry out continuous treatment in patients suffering from chronic forms. HLI may be recommended as an effective agent.
Botsvadze
E Sh
ESh
Kuznetsov
V P
VP
Aleksishvili
M M
MM
Gogichaĭshvili
Sh Sh
ShSh
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D016207:Cytokines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D006509:Hepatitis B / Q000276:immunology / Q000628:therapy*; D003699:Hepatitis D / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007273:Injections, Intramuscular; D007370:Interferon Type I / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D013997:Time Factors
D016207:Cytokines; D004338:Drug Combinations; D007370:Interferon Type I; D016898:Interferon-alpha; C062252:leukinferon
Lechenie razlichnykh form B- i del'ta-gepatitov preparatami interferona.